Disease · MONDO_0005099

subarachnoid hemorrhage

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. subarachnoid hemorrhage. Diseases, record MONDO_0005099. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005099

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: subarachnoid hemorrhage; Open Targets
Open Targets ID: MONDO_0005099; Open Targets
Other names: Aneurysmal Subarachnoid Hemorrhage, Aneurysmal Subarachnoid Hemorrhages, Hemorrhage, Aneurysmal Subarachnoid, Hemorrhage, Intracranial Subarachnoid, Hemorrhage, Perinatal Subarachnoid, Hemorrhage, Spontaneous Subarachnoid, Hemorrhage, Subarachnoid, Hemorrhages, Aneurysmal Subarachnoid, Hemorrhages, Intracranial Subarachnoid, Hemorrhages, Perinatal Subarachnoid, Hemorrhages, Spontaneous Subarachnoid, Hemorrhages, Subarachnoid, Intracranial Subarachnoid Hemorrhage, Intracranial Subarachnoid Hemorrhages, Perinatal Subarachnoid Hemorrhage, Perinatal Subarachnoid Hemorrhages, SAH, SAH (Subarachnoid Hemorrhage), SAH - Subarachnoid haemorrhage, SAHs (Subarachnoid Hemorrhage), Spontaneous Subarachnoid Hemorrhage, Spontaneous Subarachnoid Hemorrhages, Subarachnoid Hemorrhage, Aneurysmal, Subarachnoid Hemorrhage, Intracranial, Subarachnoid Hemorrhage, Perinatal, Subarachnoid Hemorrhage, Spontaneous, Subarachnoid Hemorrhages, Subarachnoid Hemorrhages, Aneurysmal, Subarachnoid Hemorrhages, Intracranial, Subarachnoid Hemorrhages, Perinatal, Subarachnoid Hemorrhages, Spontaneous, Subarachnoid aneurysmal hemorrhage, Subarachnoid haemorrhage, Subarachnoid haemorrhage NOS, Subarachnoid hemorrhage (disorder), Subarachnoid hemorrhage NOS, Subarachnoid hemorrhage NOS (disorder), subarachnoid haemorrhage (disease), subarachnoid hemorrhage (disease); Open Targets
MeSH: D013345; MeSH
Highest stage of its drugs: Approval, for 1 of its 84 drugs, from TTD; Open Targets

Drugs84

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TIRILAZAD MESYLATE	CHEMBL3989513	Small molecule	Approval	TTD	1	0	0	Drugs and targets
NIMODIPINE	CHEMBL1428	Small molecule	Phase 3	ClinicalTrials.gov and TTD	7	5	5	Drugs and targets
SODIUM CHLORIDE	CHEMBL1200574	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
CLAZOSENTAN	CHEMBL109648	Small molecule	Phase 3	ClinicalTrials.gov	4	3	3	Drugs and targets
ALTEPLASE	CHEMBL1201593	Enzyme	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
DEXMEDETOMIDINE	CHEMBL778	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
SIMVASTATIN	CHEMBL1064	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
SODIUM LACTATE	CHEMBL1357	Small molecule	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
ACETAMINOPHEN	CHEMBL112	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ACETYLCYSTEINE	CHEMBL600	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 84

See all 84 drugs

Targets90

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA1	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2562	Drugs and targets
GABRD	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2563	Drugs and targets

1 to 10 of 90

See all 90 targets

Trials75

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01095731	The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage	Phase 2	60	2025-10-29	Aneurysmal Subarachnoid Hemorrhage	TIOPRONIN	Its record names the disease	ClinicalTrials.gov
NCT02872857	Subarachnoid Hemorrhage Recovery And Galantamine	Phase 1/2	60	2021-10-08	Subarachnoid Hemorrhage	GALANTAMINE	Its record names the disease	ClinicalTrials.gov
NCT00774306	Antiepileptic Drugs and Vascular Risk Markers	Not applicable	52	2014-11-25	Subarachnoid Hemorrhage	LEVETIRACETAM, PHENYTOIN, VALPROIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00283400	Treatment of Subarachnoid Hemorrhage With Human Albumin	Not applicable	47	2015-04-01	Subarachnoid Hemorrhage	ALBUMIN HUMAN	Its record names the disease	ClinicalTrials.gov
NCT03496545	Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury	Phase 1/2	47	2021-06-24	Subarachnoid Hemorrhage, Subdural Hematoma, Traumatic Brain Injury, Ischemic Stroke, Fever, Intracerebral Hemorrhage	BROMOCRIPTINE	Its record names the disease	ClinicalTrials.gov
NCT00585559	Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm	Phase 3	44	2025-04-18	Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm	ACETAMINOPHEN, ACETYLCYSTEINE	Its record names the disease	ClinicalTrials.gov
NCT00795288	Statins and Cerebral Blood Flow in Subarachnoid Hemorrhage (SAH)	Phase 1/2	42	2015-01-16	Subarachnoid Hemorrhage	SIMVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT01024972	Safety Study of Dantrolene in Subarachnoid Hemorrhage	Phase 1/2	31	2015-03-05	Subarachnoid Hemorrhage, Cerebral Vasospasm	DANTROLENE	Its record names the disease	ClinicalTrials.gov
NCT03691727	Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)	Phase 1/2	30	2021-10-04	Subarachnoid Hemorrhage, Aneurysmal	TIROFIBAN	Its record names the disease	ClinicalTrials.gov
NCT03318783	Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial	Phase 1/2	20	2021-01-22	Subarachnoid Hemorrhage, Aneurysmal, Delayed Cerebral Ischemia, Vasospasm, Cerebral, Endothelial Dysfunction	GSK2256294	Its record names the disease	ClinicalTrials.gov

1 to 10 of 75

See all 75 trials

Comparisons in its trials22

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Galantamine vs Placebo: Mortality	1 of 30	4 of 30	60	NCT02872857	Trial comparisons
Galantamine vs Placebo: deaths from any cause	1 of 30	4 of 30	60	NCT02872857	Trial comparisons
Galantamine vs Placebo: Tolerability as Assessed by the Number of Participants Who Stop Study Medication Due to Adverse Event Possibly Associated With Study Drug	1 of 30	1 of 30	60	NCT02872857	Trial comparisons
Galantamine vs Placebo: serious adverse events	17 of 30	17 of 30	60	NCT02872857	Trial comparisons
Tiopronin, Hunt Hess Grade I-V vs Sugar Pill, Hunt Hess Grade I-V: deaths from any cause	4 of 29	3 of 27	56	NCT01095731	Trial comparisons
Tiopronin, Hunt Hess Grade I-V vs Sugar Pill, Hunt Hess Grade I-V: serious adverse events	6 of 29	9 of 27	56	NCT01095731	Trial comparisons
Acetaminophen vs Bromocriptine and Acetaminophen: deaths from any cause	0 of 21	1 of 26	47	NCT03496545	Trial comparisons
Acetaminophen vs Bromocriptine and Acetaminophen: serious adverse events	0 of 21	1 of 26	47	NCT03496545	Trial comparisons
Simvastatin vs Control: serious adverse events	0 of 21	0 of 21	42	NCT00795288	Trial comparisons
Dantrolene vs Placebo: Liver Toxicity	1 of 16	0 of 15	31	NCT01024972	Trial comparisons

1 to 10 of 22

See all 22 comparisons in its trials

Papers from its trials78

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32391156	RESULT	1	PubMed
29801906	RESULT	1	PubMed
29799344	RESULT	1	PubMed
29169472	RESULT	1	PubMed
29093065	RESULT	1	PubMed
28371181	RESULT	1	PubMed
26978207	RESULT	1	PubMed
26721259	RESULT	1	PubMed
25366638	RESULT	1	PubMed
25344064	RESULT	1	PubMed

1 to 10 of 78

See all 78 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005099

GET https://conductscience.org/api/diseases/v1/MONDO_0005099/drugs?page=2

API reference For AI assistants